Important: New Login Process
We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.
- If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
- If you log in with a username and password, you will be prompted to set a new password before accessing your account.
Go to the Login Page to get started.
We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Poseida Therapeutics Inc.
Headquarters: San Diego, CA, United States of America
Website: N/A
Year Founded: 2015
Status: Acquired
BioCentury | Jan 29, 2025
Guest Commentary
Winning over Wall Street: Biotechs’ comeback playbook — a Guest Commentary by Jami Rubin
Advice for CEOs and CFOs as they navigate the year ahead
BioCentury | Dec 3, 2024
Deals
The week in deals: Acadia taps Saniona for GABRA3 modulator, and more
Deals Report: Roche-Poseida, Novartis-PTC and Sarepta-Arrowhead forge large deals, as Idorsia keeps the lights on into 2025
BioCentury | Nov 26, 2024
Deals
Roche rewards Poseida’s shareholders with high premium in $1B takeout
If fulfilled, CVR tied to pipeline programs would drive deal’s value even further
BioCentury | May 7, 2024
Deals
Deals report: Novartis strengthens radiotherapy pipeline with pair of deals
Plus: Xyphos-Poseida to develop allogeneic CAR T therapies, Chiesi gains ex-U.S. right to Gossamer’s seralutinib, and more
BioCentury | Apr 18, 2024
Management Tracks
Protego names Warner CEO
Plus: Foghorn hires Humer and updates from Javelin, Stoke, Sensorium, Theradaptive and more
BioCentury | Mar 27, 2024
Management Tracks
Rocket names Mirati vet Ondrey CFO
Plus: Syed Rizvi joins Poseida as CMO, and updates from Tvardi, Echosens and Bicara
BioCentury | Feb 16, 2024
Product Development
Creating CAR T therapies that don’t cause cancer
Off switches and non-viral delivery technologies may be the solution to CAR Ts’ most recent safety problem
BioCentury | Dec 19, 2023
Product Development
Genentech positions bispecifics as durable options via ASH data
Fixed-duration doses of Lunsumio, Columvi led to responses that persisted long after treatment was stopped
BioCentury | Oct 10, 2023
Management Tracks
Amgen veteran Lenz named head of R&D at Neumora
Plus: Eaton leaving Editas as CTO, CBO and updates from Poseida, Zevra, Pheon, Lexicon and more
BioCentury | Aug 8, 2023
Data Byte
How Astellas’ recent deals fit its focus areas
Japanese pharma has done a dozen therapeutics deals so far this year, with at least seven showcasing how it’s building within defined focus areas
Items per page:
1 - 10 of 67